文献速递骨肌US

超声引导下增生疗法治疗肩峰附着点病与肩锁关节病变:一项单臂前瞻性研究

Ultrasound-Guided Prolotherapy for Acromial Enthesopathy and Acromioclavicular Joint Arthropathy: A Single-Arm Prospective Study.
PubMed 文献 · J Ultrasound Med · 2018-08-31

研究纳入31例慢性中重度肩痛患者,于2015年9月至2017年9月接受超声引导下15%葡萄糖溶液增生疗法注射,间隔1个月共2次。治疗后VAS评分平均降低4.3±2.6(治疗前6.8±1.5,治疗后2.5±2.1,P<.01),20例(31例中)疼痛显著减轻且无不良反应。作者认为该疗法对中重度肩峰附着点病与肩锁关节病变有效且安全。

要点

  • 超声引导下将10 mL 15%葡萄糖溶液注射至三角肌肩峰附着点或肩锁关节囊。
  • 31例中20例治疗后VAS≤3分,达到显著疼痛减轻。
  • 平均VAS评分降低4.3±2.6,治疗前6.8±1.5 vs 治疗后2.5±2.1,P<.01。

核心结论

  • 超声引导下15%葡萄糖溶液增生疗法对中重度肩峰附着点病与肩锁关节病变是有效且安全的治疗选择。

研究设计与样本

  • 单臂前瞻性研究,纳入31例慢性中重度肩痛患者,2015年9月至2017年9月招募,平均随访61.8天,采用配对t检验比较治疗前后VAS评分。

诊断标准与关键数值

  • 显著疼痛减轻定义为治疗后VAS评分≤3分;31例中20例达到该标准;平均VAS评分降低4.3±2.6(治疗前6.8±1.5 vs 治疗后2.5±2.1,P<.01)。

临床应用与阅片要点

  • 超声引导下将10 mL 15%葡萄糖溶液无菌注射至三角肌肩峰附着点或肩锁关节囊,共2次、间隔1个月;作者认为该疗法可作为中重度肩峰附着点病与肩锁关节病变的有效且安全治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Prolotherapy is an injection-based complementary treatment for various musculoskeletal diseases. The aim of this study was to evaluate the therapeutic efficacy of ultrasound-guided prolotherapy in the treatment of acromial enthesopathy and acromioclavicular joint arthropathy.

METHODS: Thirty-one patients with chronic moderate-to-severe shoulder pain were recruited from September 2015 to September 2017. Ultrasound-guided prolotherapy was performed by injecting 10 mL of a 15% dextrose solution into the acromial enthesis of the deltoid or acromioclavicular joint capsule aseptically. Prolotherapy was given in 2 sessions separated by a 1-month interval. The pretreatment-to-posttreatment change in the pain visual analog scale (VAS) score was recorded as the primary outcome. The mean follow-up duration was 61.8 days. A paired t test was used to assess the difference in pretreatment and posttreatment VAS scores. A univariate logistic regression analysis was conducted to identify the demographic variables associated with substantial pain reduction after the intervention. Substantial pain reduction was defined as a posttreatment VAS score of 3 or less.

RESULTS: Twenty of the 31 patients reported substantial pain reduction without adverse effects after the intervention. The mean VAS score reduction ± SD was 4.3 ± 2.6 (pretreatment, 6.8 ± 1.5; posttreatment, 2.5 ± 2.1; P < .01).

CONCLUSIONS: Ultrasound-guided prolotherapy with a 15% dextrose solution is an effective and safe therapeutic option for moderate-to-severe acromial enthesopathy and acromioclavicular joint arthropathy.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Hsieh PC, Chiou HJ, Wang HK, et al. Ultrasound-Guided Prolotherapy for Acromial Enthesopathy and Acromioclavicular Joint Arthropathy: A Single-Arm Prospective Study. J Ultrasound Med. 2018. PMID: 30171616. doi:10.1002/jum.14727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。